Unknown

Dataset Information

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.


ABSTRACT:

SUBMITTER: Bear HD 

PROVIDER: S-EPMC4624323 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature